Eli Lilly and Co (NYSE:LLY)
$ 806.06 -0.08 (-0.01%) Market Cap: 765.21 Bil Enterprise Value: 792.88 Bil PE Ratio: 87.14 PB Ratio: 50.92 GF Score: 87/100

Q1 2024 Eli Lilly and Co Earnings Call Transcript

Apr 30, 2024 / 02:00PM GMT
Release Date Price: $781.1 (+5.95%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2024 Earnings Call. (Operator Instructions)

I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.

Joe Fletcher
Eli Lilly and Company - VP of IR

Thank you, Paul, and good morning, everyone. Thank you for joining us for Eli Lilly and Company's Q1 2024 Earnings Call. I'm Joe Fletcher, Senior Vice President of Investor Relations. And joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Anat Ashkenazi, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Loxo at Lilly; and Patrik Jonsson, President of Lilly Diabetes and Obesity and Lilly U.S.A. We're also joined by Michaela Irons, Mike Springnether and Lauren Zierki of the IR team.

During this conference call, we anticipate making projections and forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot